CANTEX Trademark

Trademark Overview

On Wednesday, June 14, 2023, a trademark application was filed for CANTEX with the United States Patent and Trademark Office. The USPTO has given the CANTEX trademark a serial number of 98043024. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Saturday, April 18, 2026. This trademark is owned by Cantex Pharmaceuticals, Inc.. The CANTEX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases,...
cantex

General Information

Serial Number98043024
Word MarkCANTEX
Filing DateWednesday, June 14, 2023
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateSaturday, April 18, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 4, 2025

Trademark Statements

Goods and ServicesPharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code005
First Use Anywhere DateFriday, April 28, 2023
First Use In Commerce DateFriday, April 28, 2023

Trademark Owner History

Party NameCantex Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWeston, FL 33326
US
Party NameCantex Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWeston, FL 33326
US

Trademark Events

Event DateEvent Description
Saturday, June 17, 2023NEW APPLICATION ENTERED
Tuesday, July 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 4, 2024ASSIGNED TO EXAMINER
Tuesday, March 12, 2024NON-FINAL ACTION WRITTEN
Tuesday, March 12, 2024NON-FINAL ACTION E-MAILED
Tuesday, March 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 29, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, May 29, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, September 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 17, 2024SUSPENSION LETTER WRITTEN
Thursday, October 17, 2024LETTER OF SUSPENSION E-MAILED
Thursday, October 17, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, October 23, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Wednesday, October 23, 2024WITHDRAWAL OF ATTORNEY GRANTED
Monday, October 28, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, October 28, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 28, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, October 28, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, October 28, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 17, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, January 16, 2025ASSIGNED TO LIE
Thursday, January 16, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 16, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 6, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 7, 2025LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, February 26, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 4, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 4, 2025PUBLISHED FOR OPPOSITION
Tuesday, April 29, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 17, 2025SOU TEAS EXTENSION RECEIVED
Friday, October 17, 2025SOU EXTENSION 1 FILED
Friday, October 17, 2025SOU EXTENSION 1 GRANTED
Friday, October 17, 2025TEAS STATEMENT OF USE RECEIVED
Saturday, October 18, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 6, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, October 17, 2025USE AMENDMENT FILED
Saturday, April 11, 2026STATEMENT OF USE PROCESSING COMPLETE
Saturday, April 18, 2026SU - NON-FINAL ACTION - WRITTEN
Saturday, April 18, 2026NON-FINAL ACTION E-MAILED
Saturday, April 18, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

cantex diseases treatment illnesses cancer other pharmaceutical preparations namely infectious serious